Pulmonx Corporation
15
3
4
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
18%
2 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Combined Zephyr Valve System With Inter-lobar Fissure Completion for Lung Volume Reduction in Emphysema
Role: collaborator
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
Role: lead
Zephyr Etude Post-Inscription (French Registry)
Role: lead
Zephyr Valve Registry (ZEVR)
Role: lead
Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion
Role: lead
Zephyr Valve Japan Post-Marketing Surveillance
Role: lead
Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)
Role: lead
Mind The Gap - Crossing Borders Study
Role: collaborator
Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBV
Role: lead
Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)
Role: lead
To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves
Role: lead
Clinical Investigation of a Modified Staged Treatment Algorithm Using the AeriSeal System
Role: lead
A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR)
Role: lead
Safety and Feasibility Study of the Chartis System With Heterogeneous Emphysema Prior to Endobronchial Lung Volume Reduction (ELVR)
Role: lead
Safety and Feasibility Study of the Chartis System
Role: lead
All 15 trials loaded